A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

Phase

Condition

N/A

Treatment

Placebo

ABBV-8736

Clinical Study ID

NCT07141199

M25-918

Ages 18-55
All Genders
Accepts Healthy Volunteers

Study Summary

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Body mass index (BMI) is >= 18.0 to <= 32.0 kg/m^2 after rounding to the tenthsdecimal at Screening. BMI is calculated as weight in kg divided by the square ofheight measured in meters.
A condition of general good health, based upon the results of a medical history,physical examination, vital signs, laboratory profile and a 12-lead ECG.

Exclusion

Exclusion Criteria:

History of epilepsy, any clinically significant cardiac, respiratory (except mildasthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatricdisease or disorder, or any uncontrolled medical illness.
History of any clinically significant sensitivity or allergy to any medication orfood.
Prior exposure to a TREM1 agent.

Study Design